New Frontiers in the Management of Acute Coronary Syndromes: Cangrelor and Elinogrel

Author(s): Ivano Bonadei, Edoardo Sciatti, Enrico Vizzardi, Antonio D’Aloia, Riccardo Raddino, Marco Metra

Journal Name: Recent Patents on Cardiovascular Drug Discovery
Continued as Recent Advances in Cardiovascular Drug Discovery

Volume 9 , Issue 1 , 2014


The activation and aggregation of platelets at sites of vascular injury or near to implanted stent are pivotal in the development of thrombotic events during and after an acute coronary syndrome (ACS) or a percutaneous coronary intervention (PCI). For that reason, an exclusively oral dual antiplatelet treatment regimen with platelet P2Y12 receptor antagonists in addition to the cyclooxygenase inhibitor aspirin has become the cornerstone of treatment in that contest. However, every trial underlines the same problem: if maximizing antiplatelet therapy significantly attenuates ischemic events in patients with coronary artery disease, on the other side it may also increase bleeding phenomena. These limitations have prompted a search for novel antiplatelet agents with a more favorable risk–benefit ratio. Moreover, an early onset of action is desirable during PCI and an early offset after bleeding events. Two novel antiplatelet agents, Cangrelor and Elinogrel, are available in intravenous form (Elinogrel also in oral form) and expand this context. Recent trials have tested them against Clopidogrel regarding efficacy and safety outcomes.This review aimed at providing an overview on intravenous emerging compounds and recent patents in the setting of ACS and PCI.

Keywords: Acute coronary syndrome, cangrelor, elinogrel, percutaneous coronary intervention, myocardial infarction.

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 16 January, 2015
Page: [22 - 27]
Pages: 6
DOI: 10.2174/1574890109666140610153605

Article Metrics

PDF: 34